Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: Twenty-two abdominally obese insulin-resistant males (homeostasis model assessment of insulin resistance>3) were randomly assigned in a randomized crossover study to subsequent 8-week treatment periods with GFT505 (80 mg/day) or placebo, followed by a two-step hyperinsulinemic-euglycemic insulin clamp with a glucose tracer to calculate endogenous glucose production (EGP). The primary end point was the improvement in glucose infusion rate (GIR). Gene expression analysis was performed on skeletal muscle biopsy specimens. RESULTS: CONCLUSIONS:
|
Authors | Bertrand Cariou, Rémy Hanf, Stéphanie Lambert-Porcheron, Yassine Zaïr, Valérie Sauvinet, Benoit Noël, Laurent Flet, Hubert Vidal, Bart Staels, Martine Laville |
Journal | Diabetes care
(Diabetes Care)
Vol. 36
Issue 10
Pg. 2923-30
(Oct 2013)
ISSN: 1935-5548 [Electronic] United States |
PMID | 23715754
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid
- Chalcones
- Lipoproteins
- PPAR alpha
- PPAR delta
- Propionates
|
Topics |
- Adult
- Chalcones
(adverse effects, therapeutic use)
- Cross-Over Studies
- Female
- Humans
- Insulin Resistance
(physiology)
- Lipoproteins
(blood)
- Liver
(drug effects, enzymology)
- Male
- Middle Aged
- Muscle, Skeletal
(drug effects, metabolism)
- Obesity
(blood, drug therapy, metabolism)
- PPAR alpha
(agonists)
- PPAR delta
(agonists)
- Propionates
(adverse effects, therapeutic use)
|